From the *Division of Infectious Diseases, UCLA David Geffen School of Medicine, and UCLA Center for Clinical AIDS Research and Education; and †Department of Public Policy, UCLA Luskin School of Public Affairs, Los Angeles, CA.
Sex Transm Dis. 2018 Jan;45(1):8-13. doi: 10.1097/OLQ.0000000000000695.
Men who have sex with men with HIV have high sexually transmitted infection (STI) incidence. Thus, the Centers for Disease Control and Prevention (CDC) recommends at least yearly STI screening of HIV-infected individuals.
We calculated testing rates for syphilis, chlamydia, and gonorrhea among HIV-positive Californians with Medicare or Medicaid insurance in 2010. Logistic regressions estimated how testing for each bacterial STI relates to demographic and provider factors.
Fewer than two-thirds of HIV-positive Medicare and fewer than three-quarters of Medicaid enrollees received a syphilis test in 2010. Screenings for chlamydia or gonorrhea were less frequent: approximately 30% of Medicare enrollees were tested for chlamydia or gonorrhea in 2010, but higher proportions of Medicaid enrollees were tested (45%-46%). Only 34% of HIV-positive Medicare enrollees who were tested for syphilis were also screened for chlamydia or gonorrhea on the same day. Nearly half of Medicaid enrollees were tested for all 3 STIs on the same day. Patients whose providers had more HIV experience had higher STI testing rates.
Testing rates for chlamydia and gonorrhea infection are low, despite the increase in these infections among people living with HIV and their close association with HIV transmission. Interventions to increase STI testing include the following: prompts in the medical record to routinely conduct syphilis testing on blood drawn for viral load monitoring, opt-out consent for STI testing, and provider education about the clinical importance of STIs among HIV-positive patients. Last, it is crucial to change financial incentives that discourage nucleic acid amplification testing for rectal chlamydia and gonorrhea infections.
男男性行为者中的 HIV 感染者性传播感染(STI)发病率较高。因此,疾病控制与预防中心(CDC)建议对 HIV 感染者至少每年进行一次 STI 筛查。
我们计算了 2010 年加利福尼亚州有医疗保险或医疗补助的 HIV 阳性者中梅毒、衣原体和淋病的检测率。逻辑回归估计了每一种细菌性 STI 的检测与人口统计学和提供者因素的关系。
不到三分之二的 HIV 阳性医疗保险者和不到四分之三的医疗补助受助人在 2010 年接受了梅毒检测。衣原体或淋病的筛查率较低:2010 年约有 30%的医疗保险受助人接受了衣原体或淋病检测,但更多的医疗补助受助人接受了检测(45%-46%)。只有 34%的 HIV 阳性医疗保险受助人在接受梅毒检测的同一天也接受了衣原体或淋病检测。近一半的医疗补助受助人在同一天接受了所有 3 种 STI 的检测。其提供者有更多 HIV 经验的患者 STI 检测率更高。
尽管 HIV 感染者中衣原体和淋病感染的发病率有所增加,且与 HIV 传播密切相关,但衣原体和淋病感染的检测率仍然很低。增加 STI 检测的干预措施包括以下几点:在用于病毒载量监测的血液采集时,在病历中设置提示,以常规进行梅毒检测;默认同意进行 STI 检测;以及对 HIV 阳性患者中 STI 的临床重要性进行提供者教育。最后,必须改变阻碍对直肠衣原体和淋病感染进行核酸扩增检测的财务激励措施。